Volume 67, Issue 1, Pages (January 2005)

Slides:

Advertisements

Similar presentations

Tazeen H. Jafar, M.D., M.P.H. Professor of Medicine Head, Section of Nephrology Department of Medicine and Community Health Sciences Aga Khan University,

Advertisements

Urine Potassium Excretion, Kidney Failure, and Mortality in CKD

Vitamin D levels and patient outcome in chronic kidney disease

Reduced renal function in patients with simple renal cysts

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Robert C. Stanton, MD American Journal of Kidney Diseases

Volume 54, Issue 2, Pages (August 1998)

Renal Function Testing

Volume 58, Issue 1, Pages (July 2000)

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,

Volume 61, Issue 4, Pages (April 2002)

Membranous nephropathy: When and how to treat

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

The risk of hospitalization and modality failure with home dialysis

Volume 57, Issue 5, Pages (May 2000)

Volume 53, Issue 4, Pages (April 1998)

Volume 81, Issue 7, Pages (April 2012)

Higher systolic blood pressure is associated with progression of carotid intima–media thickness in patients with chronic kidney disease Jessica Kendrick,

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 9, Pages (November 2011)

Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz

Volume 90, Issue 3, Pages (September 2016)

GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta- analysis of Treatment Effects From 37 Randomized Trials Lesley A.

Robert C. Stanton, MD American Journal of Kidney Diseases

Progression of diabetic nephropathy

Comorbidity and confounding in end-stage renal disease

Renal risk scores: Progress and prospects

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Jennifer E. Flythe, Stephen E. Kimmel, Steven M. Brunelli

Volume 67, Pages S48-S51 (January 2005)

Volume 86, Issue 3, Pages (September 2014)

Volume 361, Issue 9352, Pages (January 2003)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Volume 68, Issue 2, Pages (August 2005)

Volume 58, Issue 1, Pages (July 2000)

Vitamin D levels and patient outcome in chronic kidney disease

Volume 53, Issue 4, Pages (April 1998)

Proteinuria and hypertensive nephrosclerosis in African Americans

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 67, Pages S52-S54 (January 2005)

Reduced renal function in patients with simple renal cysts

Counteracting progression of renal disease: A look into the future

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease C.P. Kovesdy, S. Ahmadzadeh,

Volume 81, Issue 9, Pages (May 2012)

Volume 60, Issue 1, Pages (July 2001)

Arjang Djamali, Christina Kendziorski, Peter C. Brazy, Bryan N. Becker

Volume 58, Issue 1, Pages (July 2000)

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 79, Issue 4, Pages (February 2011)

The course of the remnant kidney model in mice

Volume 53, Issue 6, Pages (June 1998)

Cystinuria subtype and the risk of nephrolithiasis1

The Danish Renal Biopsy Register

Volume 68, Issue 5, Pages (November 2005)

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 3, Pages (September 2001)

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

Volume 53, Issue 5, Pages (May 1998)

Importance of blood pressure control in hemodialysis patient survival

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Volume 53, Issue 5, Pages (May 1998)

Friends, social networks, and progressive chronic kidney disease

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Volume 67, Issue 4, Pages (April 2005)

Volume 57, Pages S44-S48 (April 2000)

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 67, Issue 1, Pages 265-271 (January 2005) The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease Tazeen H. Jafar, Paul C. Stark, Christopher H. Schmid, Svend Strandgaard, Anne-Lise Kamper, Giuseppe Maschio, Gavin Becker, Ronald D. Perrone, Andrew S. Levey, M.D., M.P.H. Kidney International Volume 67, Issue 1, Pages 265-271 (January 2005) DOI: 10.1111/j.1523-1755.2005.00077.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Effect of angiotensin-converting enzyme (ACE) inhibitor treatment. (A) Decline in urine protein excretion in patients with polycystic kidney disease (PKD). Symbols show the difference in mean decline in urine protein excretion (95% CI) at various levels of baseline urine protein excretion in patients with PKD receiving antihypertensive treatment regimens with versus those without ACE inhibitors. Results are from a multivariable model with covariates include assignment to ACE inhibitor vs. control group, gender, age, baseline systolic blood pressure, baseline urine protein excretion, baseline serum creatinine concentration, and interaction of baseline urine protein excretion and treatment with ACE inhibitors. (B) Relative risk (95% CI) of kidney disease progression in patients with PKD. Symbols show the relative risk (95% CI) of kidney disease progression (the combined outcome of doubling of baseline serum creatinine or the onset of kidney failure) at various levels of baseline urine protein excretion in patients with PKD receiving antihypertensive treatment regimens with versus those without ACE inhibitors. Results are from a multivariable model with covariates include assignment to ACE inhibitor vs. control group, gender, age, baseline systolic blood pressure, baseline urine protein excretion, baseline serum creatinine concentration, and interaction of baseline urine protein excretion and treatment with ACE inhibitors. Kidney International 2005 67, 265-271DOI: (10.1111/j.1523-1755.2005.00077.x) Copyright © 2005 International Society of Nephrology Terms and Conditions